Clinical Trial Update: Trilaciclib for the Prevention of Chemoradiotherapy-Induced Myelosuppression in Esophageal Squamous Cell Carcinoma

View source ↗

Summary

Clinical trial update indicates ongoing recruitment for trilaciclib to prevent chemoradiotherapy-induced myelosuppression in esophageal squamous cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• trilaciclib (trilaciclib)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: ESCC | Status: RECRUITING